Unknown

Dataset Information

0

Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up.


ABSTRACT: To report long-term follow up of a phase II, single-arm trial of resectable pancreatic ductal adenocarcinoma (PDAC) treated with adjuvant interferon-based chemoradiation followed by gemcitabine to determine survival, recurrence, and complications.From 2002 to 2005, 53 patients with PDAC underwent pancreaticoduodenectomy and received adjuvant interferon-based chemoradiation consisting of external-beam irradiation and simultaneous 3-drug chemotherapy of continuous daily 5-fluorouracil infusion, weekly intravenous bolus cisplatin, and subcutaneous interferon-?, followed by two months of weekly intravenous gemcitabine.Actual overall survival for the 5- and 10-year periods were 26% and 10%, respectively, with a median overall survival of 25 months (95% CI: 16.4-38.5). Adverse prognostic factors on multivariate analysis were positive tumor margin (p < 0.035), lymphovascular invasion (p < 0.015), and perineural invasion (p < 0.026). Median time to recurrence was 11 months. Positive tumor margin was associated with lymph node involvement (p < 0.005), portal vein resection (p < 0.038), and metastases (p < 0.018). Late complications were frequent and predominated by gastrointestinal and infectious complications.Adjuvant interferon-based chemoradiation for PDAC improves long-term survival compared to standard therapy. However, recurrence rates and long-term complications remain high, thus further studies are indicated to assess patient characteristics that indicate a favorable treatment profile.

SUBMITTER: Ohman KA 

PROVIDER: S-EPMC5422112 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up.

Ohman Kerri A KA   Liu Jingxia J   Linehan David C DC   Tan Marcus C MC   Tan Benjamin R BR   Fields Ryan C RC   Strasberg Steven M SM   Hawkins William G WG  

HPB : the official journal of the International Hepato Pancreato Biliary Association 20170203 5


To report long-term follow up of a phase II, single-arm trial of resectable pancreatic ductal adenocarcinoma (PDAC) treated with adjuvant interferon-based chemoradiation followed by gemcitabine to determine survival, recurrence, and complications.<h4>Methods</h4>From 2002 to 2005, 53 patients with PDAC underwent pancreaticoduodenectomy and received adjuvant interferon-based chemoradiation consisting of external-beam irradiation and simultaneous 3-drug chemotherapy of continuous daily 5-fluoroura  ...[more]

Similar Datasets

| S-EPMC6776797 | biostudies-literature
| S-EPMC3157965 | biostudies-literature
| S-EPMC3997614 | biostudies-other
| S-EPMC8551988 | biostudies-literature
2015-10-01 | GSE60646 | GEO
| S-EPMC10082313 | biostudies-literature
| S-EPMC6893654 | biostudies-literature
| S-EPMC5988658 | biostudies-literature
2005-01-18 | GSE1907 | GEO
| S-EPMC4815888 | biostudies-other